Substrates: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
In a ''substrate reduction therapy'' a small molecule inhibitor ([[Acid beta-glucosidase with N-nonyl-deoxynojirimycin|Zavesca™]]) is used to inhibit the synthesis of the accumulated glucosylceramide. | In a ''substrate reduction therapy'' a small molecule inhibitor ([[Acid beta-glucosidase with N-nonyl-deoxynojirimycin|Zavesca™]]) is used to inhibit the synthesis of the accumulated glucosylceramide. | ||
NADH quinone oxidoreductase (NQO1) substrates | '''NADH quinone oxidoreductase (NQO1) substrates''' | ||
Quinones (including duroquinone (2,3,5,6-tetramethyl-''p''-benzoquinone) are substrates of NQO1 (it catalyzes two-electron reduction of them to hydroquinones). Duroquinone <font color='black'><b>(yellow)</b></font> binds to the <scene name='2f1o/Align1/4'>active site</scene> by interactions involving the FAD and several hydrophobic and hydrophilic residues in the duroquinone-NQO1 complex ([[1dxo]]). | Quinones (including duroquinone (2,3,5,6-tetramethyl-''p''-benzoquinone) are substrates of NQO1 (it catalyzes two-electron reduction of them to hydroquinones). Duroquinone <font color='black'><b>(yellow)</b></font> binds to the <scene name='2f1o/Align1/4'>active site</scene> by interactions involving the FAD and several hydrophobic and hydrophilic residues in the duroquinone-NQO1 complex ([[1dxo]]). | ||
Revision as of 15:10, 14 October 2021
| ||||||||||||